Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AMX0035

Small molecule · developed by Amylyx Pharmaceuticals

Phase 2/3 Most advanced trial (none active)

AMLX Developer

1 Registered trials

What is AMX0035?

AMX0035 is a proprietary formulation of sodium phenylbutyrate and taurursodiol. It is studied in progressive supranuclear palsy, a neurodegenerative atypical parkinsonism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Neurology
Developer: Amylyx Pharmaceuticals Inc. (AMLX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06122662	Phase 2/3	Progressive Supranuclear Palsy	Completed	AMLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atypical ParkinsonismNeurodegenerative DiseasesProgressive Supranuclear PalsyPSP

More from Amylyx Pharmaceuticals

AMX0114 Phase 1 Avexitide Phase 3

Sources

ClinicalTrials.gov NCT06122662

Updated Oct 11, 2026. Something wrong or missing? Report it on the AMLX page.

Follow AMLX, the company behind AMX0035

See AMLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMLX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z